Wells Fargo Lowers Monster Beverage (MNST) Price Target to $90

Monster Beverage Corporation (NASDAQ:MNST) is one of the 15 Set-It-and-Forget-It Stocks to Buy in 2026.

Wells Fargo Lowers Monster Beverage (MNST) Price Target to $90

On March 16, 2026, Monster Beverage Corporation (NASDAQ:MNST)’s price target from Wells Fargo was lowered from $94 to $90. Wells Fargo analyst kept an Overweight rating on the stock. The firm maintains a positive outlook on Monster Beverage Corporation (NASDAQ:MNST) amid post-earnings stock declines and concerns over growth deceleration. Following a sales analysis, analysts believe growth remains durable with catalysts ahead.

In another development, on March 11, 2026, Jefferies maintained a Buy rating on Monster Beverage Corporation (NASDAQ:MNST) while keeping its price target at $100. The firm characterized the recent 11% share decline as a buying opportunity. Jefferies attributes the pullback to “near-term noise,” including increases in gas prices, market share gains by Red Bull, and geopolitical uncertainty. However, amid these headwinds, the firm expresses confidence in the company’s long-term fundamentals. It cited resilient U.S. energy category and new food service avenues in addition to international and affordable initiatives as growth drivers that are anticipated to provide incremental upside.

Founded in 1985, Monster Beverage Corporation (NASDAQ:MNST) is an American beverage company that operates through brands such as Monster Energy, Reign, and Bang to develop, market, sell, and distribute energy drinks. Its headquarters is in California.

While we acknowledge the risk and potential of MNST as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MNST and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Space Exploration Stocks to Buy According to Analysts and 10 Best Diagnostics and Research Stocks to Buy According to Analysts

Disclosure: None.  Follow Insider Monkey on Google News.